• Directory of Taiwan

Bronchodilators Market Trends for 2023 Insights and Analysis

The report presents a comprehensive overview of industry trends, growth share and the competitive landscape in 200 pages.

The most recent research study on the global “Bronchodilators Market” [2023-2030] by Report Ocean provides a description of the segments and sub-segments. It offers a thorough examination of the sector, analyses historical data, forecasts the future, and aids in understanding the market situation, growth prospects, and difficulties.

Request To Download Sample of This Strategic Report:

Global Bronchodilators Market is valued at approximately USD 33.78 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5.2% over the forecast period 2022-2029.

A bronchodilator is a type of drug that relaxes the muscles in the lungs (bronchi) airway passageways and widens them to make breathing easier. They enhance airflow within the lungs and lessen resistance in the respiratory tract. Additionally, bronchodilators are utilized to lessen pulmonary mucus. These medications are taken by patients with respiratory conditions using inhalers or nebulizers. Inhalation bronchodilators additionally influence mucociliary clearance. By relaxing the muscles in the lungs and enlarging the airways, bronchodilators are employed in the treatment of obstructive lung disorders (bronchi). The growing awareness regarding the treatment of lung diseases, increasing geriatric population, coupled with the rise in number of smokers are the primary factors that are fostering the market demand across the globe.

The rising prevalence of lung diseases is acting as a chief driving factor for the growth of the global market. For instance, the World Health Organization (WHO) lists respiratory disease infections as the third leading cause of mortality, accounting for around 3 million deaths per year (or 6% of all fatalities worldwide), with nearly 90% of COPD fatalities occurring in individuals over 70 from low- and middle-income nations. Also, it is estimated that 262 million people worldwide have asthma, which typically affects youngsters. Thus, the high incidences of various respiratory and lung diseases are augmenting the market demand at a substantial rate. Moreover, the heightened pollution levels globally, as well as the growing R&D investments related to bronchodilators are presenting various lucrative opportunities over the forecasting years. However, the adverse effects of bronchodilators and long approval times and stringent regulations are hindering the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Bronchodilators Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing awareness regarding the treatment of COPD, asthma, and other chronic respiratory disorders, along with the rising number of government initiatives. Whereas, the Asia Pacific is also expected to grow with the highest CAGR during the forecast period, owing to factors such as the high presence of respiratory disorder patient pool, improving healthcare infrastructure, and rise in demand for bronchodilators in the pharmaceutical sector across the regional market.

Major market players included in this report are:
Abbott Laboratories
AstraZeneca plc.
Boehringer Ingelheim International GmbH
GlaxoSmithKline Plc.
F. Hoffmann-La Roche Ltd.
Novartis AG.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Vectura Group Plc

Download Sample of This Strategic Report:

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below.

By Indication:
Chronic obstructive pulmonary disease (COPD)

By Drug Type:
Phosphodiesterase Inhibitor
Combination Drugs

By Route Of Administration:

Download Sample of This Strategic Report:

By Region:
North America
Asia Pacific
South Korea
Latin America
Rest of the World

Request Full Report

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom-line goals which will boost your market share in today’s competitive environment. Report Ocean is a ‘one-stop solution’ for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:
Report Ocean:
Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 – UNITED STATES
Tel:+1 888 212 3539 (US – TOLL FREE)